Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease (SSc-ILD).

[Joelf]

Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease (SSc-ILD).

 

Significantly favorable transitions from both ground glass and lung fibrosis ILD patterns to normal lung were found in patients undergoing immunosuppressive treatment for Ssc-ILD. PubMed, Arthritis Rheumatol, 08/20/2019. (Also see Cyclophosphamide and Cellcept)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.